REVB: Revelation Biosciences, Inc. Stock

by  •  • Comments Off on REVB: Revelation Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.60
Enterprise Value ($M) -4.94
Book Value ($M) 2.67
Book Value / Share 6.62
Price / Book 0.60
NCAV ($M) 2.59
NCAV / Share 6.42
Price / NCAV 0.62

Profitability (mra)
Return on Invested Capital (ROIC) -5.80
Return on Assets (ROA) -1.27
Return on Equity (ROE) -2.33

Liquidity (mrq)
Quick Ratio 1.64
Current Ratio 1.64

Balance Sheet (mrq) ($M)
Current Assets 6.66
Assets 6.74
Liabilities 4.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Lind Global Fund II LP 2.90 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 61,293 188,018 32.60
2025-02-03 25,582 89,687 28.52
2025-01-31 113,414 293,453 38.65
2025-01-30 139,277 382,383 36.42

(click for more detail)

Similar Companies
PULM – Pulmatrix, Inc. QLGN – Qualigen Therapeutics, Inc.
RENB – Renovaro Inc. RGC – Regencell Bioscience Holdings Limited
RGLS – Regulus Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io